Skip to main content

Table 3 Treatment-emergent Adverse Events That Occurred in ≥10% of Patients

From: Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

TEAEa Patients Treated With Lenvatinib 24 mg Once Daily (N = 26)
Patients with any-grade TEAE, n (%) 26 (100)
Patients with any TEAE ≥ grade 3, n (%) 21 (80.8)
Preferred term, n (%) Any grade Grade 3 or 4
Hypertension 22 (84.6) 10 (38.5)
Dysphonia 16 (61.5) 0
Proteinuria 16 (61.5) 3 (11.5)
Palmar-plantar erythrodysesthesia syndrome 15 (57.7) 3 (11.5)
Decreased appetite 14 (53.8) 3 (11.5)
Thrombocytopenia 14 (53.8) 1 (3.8)
Fatigue 13 (50.0) 0
Hypothyroidism 12 (46.2) 0
Peripheral edema 9 (34.6) 0
Constipation 8 (30.8) 0
Decreased weight 8 (30.8) 0
Diarrhea 8 (30.8) 1 (3.8)
Pyrexia 8 (30.8) 0
Anemia 6 (23.1) 3 (11.5)
Cholangitis 6 (23.1) 4 (15.4)
Nausea 6 (23.1) 0
Rash 6 (23.1) 1 (3.8)
Upper abdominal pain 6 (23.1) 0
Malaise 5 (19.2) 0
Ascites 4 (15.4) 2 (7.7)
Cancer pain 4 (15.4) 0
Headache 4 (15.4) 0
Myalgia 4 (15.4) 0
Stomatitis 4 (15.4) 0
Tumor pain 4 (15.4) 0
Alopecia 3 (11.5) 0
Bile duct obstruction 3 (11.5) 2 (7.7)
Delirium 3 (11.5) 0
Epistaxis 3 (11.5) 0
Hypoalbuminemia 3 (11.5) 2 (7.7)
Hypophosphatemia 3 (11.5) 1 (3.8)
Lymphopenia 3 (11.5) 2 (7.7)
Pruritis 3 (11.5) 0
Vomiting 3 (11.5) 0
  1. TEAE treatment-emergent adverse event
  2. aTEAEs were any adverse events that occurred between initiation of treatment and 30 days from last dose
\